Chronic Hepatitis Delta Virus Infection Market 2026: Current Scenario, Momentum, and What's Next for the 8MM Landscape | Thelansis

Executive Summary
The chronic Hepatitis Delta Virus (HDV) infection space has moved faster in the past twelve months than in the previous decade combined. Long dismissed as a "forgotten" hepatitis, HDV, the most severe and rapidly progressive form of viral hepatitis, occurring only as a co-infection with Hepatitis B, is finally getting the clinical and commercial attention it warrants.
The turning point: on May 22, 2026, the US FDA granted accelerated approval to Hepcludex (bulevirtide-gmod), Gilead Sciences' first-in-class entry inhibitor, making it the first-ever FDA-approved treatment for chronic HDV infection in the United States. Until that date, US clinicians had no approved antiviral option and relied on off-label, interferon-based regimens with modest efficacy.
This approval, layered on top of bulevirtide's earlier conditional approval in the EU, effectively opens up the US as a commercial market for the first time and is expected to catalyze HBV/HDV reflex testing, diagnosis rates, and treatment initiation across all 8 Major Markets, including China, which carries the largest absolute number of HDV RNA-positive individuals globally.

Against this backdrop, our two latest reports break down where the HDV market stands today and where it's headed through 2036 - epidemiology, competitive dynamics, forecasts, emerging pipeline assets, unmet needs, and Target Product Profile (TPP) expectations from treating physicians and payers.

See the full epidemiology, competitive landscape, and 10-year market forecast: https://thelansis.com/reports/chronic-hepatitis-delta-virus-hdv-infection-market-outlook-forecast-2026-to-2036/

Key Current Therapies / Standard of Care
For years, chronic HDV management leaned almost entirely on off-label pegylated interferon-alfa, an approach limited by poor tolerability, modest sustained virologic response, and contraindications in patients with decompensated cirrhosis. That picture has now shifted meaningfully:
• Hepcludex (bulevirtide), a first-in-class NTCP entry inhibitor that blocks HDV and HBV from entering hepatocytes, is approved in the EU (conditional, since 2020) and now in the US (accelerated approval, May 2026) for adults with chronic HDV and compensated liver disease.
• Pivotal Phase 3 MYR301 data underpinning the US approval showed a 48% combined virologic and biochemical response at Week 48 with bulevirtide 8.5 mg daily versus 2% in the delayed-treatment arm, with undetectable HDV RNA rising to 50% by Week 144, evidence of a response that deepens with continued therapy.
• A boxed warning around severe hepatitis flares after treatment discontinuation underscores that bulevirtide, as currently indicated, functions as a long-term suppressive therapy rather than a finite cure, a gap the next wave of pipeline assets is directly targeting.
• Off-label interferon-based regimens, sometimes combined with bulevirtide, remain in use in several 8MM geographies, particularly where reimbursement or access barriers limit entry-inhibitor uptake.

Key Emerging Players or Therapies
The pipeline behind bulevirtide is arguably the more consequential story for the 2026-2036 decade, with multiple mechanisms converging to push toward finite, potentially curative regimens:
• Tobevibart + Elebsiran (Vir Biotechnology, licensed to Norgine for commercialization), a monoclonal antibody plus siRNA combination in the Phase 3 ECLIPSE registrational program (ECLIPSE 1, 2, and 3). Updated Phase 2 SOLSTICE data presented at EASL 2026 showed undetectable HDV RNA maintained in 88% of evaluable participants through 96 weeks, alongside meaningful HBsAg declines. ECLIPSE 1 completed enrollment, with topline data expected in Q1 2027.
• Brelovitug (Bluejay Therapeutics), a next-generation entry-inhibitor class asset advancing through clinical development as part of the broader multi-targeted treatment shift.
• Additional siRNA, entry-inhibitor, and combination approaches remain in earlier-stage development, reflecting growing investor and pharma confidence that HDV is now a viable, de-risked therapeutic category rather than a niche indication.
• Licensing activity (e.g., Vir-Norgine) signals that large and specialty pharma see meaningful commercial upside once regulatory pathways in the US and EU mature.

Get the full competitive and emerging-therapy breakdown, including pipeline maturity and positioning: https://thelansis.com/reports/chronic-hepatitis-delta-virus-infection-emerging-therapy-with-unmet-needs-and-tpp-insights/?utm_source=openpr&utm_medium=pr&utm_campaign=hdv_tpp

Key Market Drivers / Trends
• Landmark US approval: The May 2026 FDA accelerated approval for Hepcludex removes the single biggest structural barrier to US market entry and is expected to meaningfully lift treated patient volumes across the forecast period.
• Reflex testing momentum: With an approved therapy now available, the long-standing "why test if there's nothing to treat" mindset among US clinicians is fading fast, and reflex HDV testing in HBsAg-positive patients is gaining traction, a dynamic expected to expand the diagnosed and treatable population.
• China's outsized burden: China carries the largest absolute number of HDV RNA-positive individuals of any country worldwide, making it a pivotal market for future access, pricing, and local development strategies within the 8MM.
• Underlying disease burden: Global estimates place anti-HDV seropositivity as high as 48-72 million coinfections, with 70% or higher lifetime progression risk to cirrhosis, liver cancer, or liver failure - a burden that continues to justify premium pricing and prioritized regulatory pathways.
• Shift toward finite regimens: Combination mechanisms (entry inhibitor + antibody + siRNA) are moving the field from indefinite suppressive therapy toward the possibility of treatment-free remission, a trend that will reshape market segmentation and pricing models over the next decade.

Explore the full market drivers, pricing dynamics, and 8MM-level forecast assumptions: https://thelansis.com/reports/chronic-hepatitis-delta-virus-hdv-infection-market-outlook-forecast-2026-to-2036/?utm_source=openpr&utm_medium=pr&utm_campaign=hdv_mo

Key Unmet Need & KOL Expectations
Despite the recent progress, physicians and payers we've engaged with continue to flag persistent gaps:
• Diagnosis remains the biggest bottleneck, most HBsAg-positive patients globally are still never reflex-tested for HDV, meaning a large share of the true patient pool stays invisible to the market.
• Current entry-inhibitor therapy requires long-term, often indefinite dosing, with a recognized risk of severe hepatitis flare on discontinuation, KOLs consistently point to durable, treatment-free response as the next milestone to chase.
• Access and affordability vary sharply across the 8MM, with reimbursement pathways, specialist referral networks, and diagnostic infrastructure all lagging in several geographies, including parts of Asia-Pacific.
• There remains no validated, easily deployable point-of-care HDV RNA test, which continues to slow real-world screening cascades even where clinical awareness has improved.

TPP Insights
Drawing from our TPP analysis, physicians and payers converge around a fairly consistent ideal profile for next-generation HDV therapies:
• Finite treatment duration with a durable, treatment-free virologic response, rather than indefinite suppressive dosing.
• A favorable, differentiated safety profile, particularly around discontinuation-related flare risk, a known limitation of current entry-inhibitor monotherapy.
• Convenient administration (reduced injection frequency or combination dosing) to support long-term adherence.
• Efficacy across a broader range of disease severity, including patients with more advanced fibrosis or cirrhosis who are often underrepresented in pivotal trials.
• Clear, defensible value-based pricing that reflects both the severity of the underlying disease and payers' scrutiny of ultra-orphan and near-orphan indications.

Dive deeper into the full TPP framework and unmet-need prioritization: [Insert Report Link - Emerging Therapy, Unmet Needs & TPP Insights Report]

Commercial Opportunity
The combination of a newly opened US market, a maturing late-stage pipeline, and a persistently underdiagnosed global patient pool positions chronic HDV as one of the more compelling infectious-disease commercial opportunities heading into the next decade. First movers with differentiated efficacy, safety, or convenience stand to capture meaningful share as diagnosis rates climb and as China and other high-burden 8MM geographies scale up screening and access infrastructure. For biopharma companies, payers, and investors tracking this space, understanding country-level epidemiology, competitive timing, and evolving TPP expectations will be critical to commercial planning over 2026-2036.

Our two reports covering Market Outlook, Epidemiology, Competitive Landscape & Forecast (2026-2036), and Emerging Therapy, Unmet Needs & TPP Insights (2026) together give a complete, decision-ready view of the chronic HDV landscape across the 8 Major Markets, including China.

CONTACT:
Himanshi Negi
Manager - Global BD and Partnering
Thelansis Knowledge Partners LLP
Email: n.himanshi@thelansis.com
Phone: +91-9560149525
Website: www.thelansis.com
Reach us at: clientsupport@thelansis.com

ABOUT THELANSIS:
Thelansis is a global healthcare market intelligence company providing strategic insights to global pharmaceutical, biotechnology, and life sciences organizations. Through proprietary epidemiology models, primary research, physician interviews, payer analysis, and commercial forecasting, Thelansis enables organizations to make informed decisions across product development, market access, and commercialization.
In addition, Thelansis offers EpiLansis, an AI-powered cloud intelligence platform that enables interactive exploration of patient populations, epidemiology trends, treatment utilization, and market dynamics across multiple therapeutic areas.
For more information about Thelansis and its disease intelligence solutions, visit www.thelansis.com or contact the team at clientsupport@thelansis.com.

This release was published on openPR.